Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
No Benzodiazepine-Like Problems Importantly, Selank does not produce the problematic effects associated with benzodiazepines: no sedation or drowsiness allowing normal daily activities, no cognitive impairment or memory problems, no psychomotor slowing or coordination issues, no tolerance development requiring dose escalation, no physical dependence or addiction potential, and no withdrawal syndrome upon discontinuation
Current treatment for STC includes dietary management, physical exercise, enemas, drug treatment, biofeedback psychosocial treatments, and surgical treatment (Corsetti and Tack, 2014)
Natural killer (NK) cells, macrophages, and lymphocytes are immune cells whose activity is regulated by glutathione
